Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Increase in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 16,800 shares, a growth of 60.0% from the March 31st total of 10,500 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average trading volume of 27,800 shares, the short-interest ratio is currently 0.6 days.

Barinthus Biotherapeutics Trading Up 19.2 %

BRNS stock opened at $1.00 on Wednesday. The firm has a market cap of $40.33 million, a P/E ratio of -0.67 and a beta of -0.77. The stock’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.03. Barinthus Biotherapeutics has a 12-month low of $0.64 and a 12-month high of $2.59.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $14.97 million for the quarter. On average, research analysts forecast that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on BRNS shares. Alliance Global Partners reiterated a “buy” rating on shares of Barinthus Biotherapeutics in a research note on Monday, March 24th. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Barinthus Biotherapeutics in a research note on Friday, March 21st.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises about 0.0% of Gilead Sciences Inc.’s portfolio, making the stock its 14th largest position. Gilead Sciences Inc. owned 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.